Aortic Valve (TAVR/TAVI)Monday, October 19, 2026
Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position - MarketBeat
1 min read·By E. Nolan Beckett, MD·Source: MarketBeat
From The Valve Wire
Access-site strategy is the next place TAVR outcomes get refined, and a 600-patient trial is now locked.
The Freiburg-Bad Krozingen group's radial versus femoral secondary access study moved to active, not recruiting.
Editor’s take pending for this article; this is the section commentary excerpt.
Source Abstract
Edwards Lifesciences Corporation $EW Stock: Birch Hill Investment Advisors LLC Trims Position MarketBeat
Read the Original
Full article at MarketBeat
Open at MarketBeat →The Valve Wire summarizes; we link out to primary sources for verification.
More in Aortic Valve (TAVR/TAVI)
- Aortic Valve (TAVR/TAVI)· Acta cardiologicaIntravascular imaging improves outcomes in left main PCI: insights from acute and chronic presentations.
- Aortic Valve (TAVR/TAVI)· Journal of nursing managementDevelopment and Initial Psychometric Validation of a Nurse-Assessed Discharge Readiness Scale for Patients With Coronary Heart Disease Following Percutaneous Coronary Intervention.
- Aortic Valve (TAVR/TAVI)· CureusUnmasking Brugada Syndrome With Oral Propafenone in a Resource-Limited Setting: A Case Report.
Elsewhere in Today’s Issue
- Mitral Valve (Repair & Replacement)· Annali italiani di chirurgiaMultidimensional Echocardiographic Parameters Predict Left Ventricular Functional Recovery After Coronary Artery Bypass Grafting.
- Mitral Valve (Repair & Replacement)· Medical Product OutsourcingFDA Flags Edwards TMVR Delivery System After Fatality - Medical Product Outsourcing
- Mitral Valve (Repair & Replacement)· IndexBoxTissue Mitral Valve Replacements Market Forecast to 2035, Driven by Aging Population and Transcatheter Innovation - IndexBox